Iminosugars, where the endocyclic oxygen of sugars is replaced by a basic nitrogen, constitute a class of carbohydrate analogues that has received considerable attention in recent years.
Subsequent research has identified iminosugars as inhibitors of a broader range of enzymes and the class is providing leads for a variety of diseases including viral infections and tumour metastasis as well as diabetes and lysosomal storage disorders.
A forthcoming meeting, organised by Summit Corporation plc, will cover both historical and future perspectives of iminosugars. Entitled “Iminosugars: Past, Present and Future – Medicines for tomorrow”, the meeting will be held at St John’s College, Oxford (UK) on 28th June. The full programme and registration details can be found on the Summit website.